As of late September 2025, new Alzheimer’s drugs like lecanemab and donanemab show promise in slowing disease progression but require early diagnosis and carry risks. The UK’s NHS and Australia face challenges in access and funding, while the UAE highlights the need for improved awareness and infrastructure. Meanwhile, the UK’s rollout of weight-loss drug Mounjaro is underfunded, limiting patient access amid rising demand and GP shortages.